Dryocrassin ABBA |
Catalog No.GN10699
One-Click Copy Product Info
|
Dryocrassin ABBA is an orally active phloroglucinol derivative with antiviral and antibacterial activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 12777-70-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Dryocrassin ABBA is an orally active phloroglucinol derivative with antiviral and antibacterial activities[1][2]. Dryocrassin ABBA not only exhibits inhibitory activity against the neuraminidases (NAs) of the H7N9 influenza virus, with an IC50 of 3.6μM[2]; but also inhibits the SrtA enzyme of Staphylococcus aureus (S. aureus), with an IC50 of 24.17μM[3].
In vitro, pretreatment of mouse bone marrow-derived DCs (mBM-DCs) with 10 or 20μM Dryocrassin ABBA 1h before lipopolysaccharide (LPS) stimulation significantly reduced the LPS-induced emission of tumor necrosis factor-a, interleukin-6, and interleukin-12p70 without affecting cell viability[4].Treatment of HepG2 cells with 25, 50, and 75μg/mL Dryocrassin ABBA for 48h inhibited the growth of HepG2 cells in a concentration-dependent manner[5].
In vivo, oral administration of Dryocrassin ABBA with different concentration(12.5, 18, and 33mg/kg) for 7 days on SPF BALB/C female mice inoculated intra-nasally with H5N1 viruses significantly reduced mortality, prolonged survival rate, and increased body weight throughout the infection period. Moreover, 33 and 18mg/kg Dryocrassin ABBA have decreased lung index and virus loads, and significantly increased MCP-1 and IL-10 while significantly decreased IL-12, IL-6, IFN-γ and TNF-α compared to the untreated group[6]. Subcutaneous injection of Dryocrassin ABBA(100mg/kg) every 12h for 96h can attenuate injury and inflammation of mouse lung tissues caused by S. aureus and increase survival of mice[7].
References:
[1] Jin, Y. H., Jeon, S., Lee, J., Kim, S., Jang, M. S., Park, C. M., Song, J. H., Kim, H. R., & Kwon, S. (2022). Anticoronaviral Activity of the Natural Phloroglucinols, Dryocrassin ABBA and Filixic Acid ABA from the Rhizome of Dryopteris crassirhizoma by Targeting the Main Protease of SARS-CoV-2. Pharmaceutics, 14(2), 376.
[2] Hou, B., Liu, Z., Yang, X. B., Zhu, W. F., Li, J. Y., Yang, L., Reng, F. C., Lv, Y. F., Hu, J. M., Liao, G. Y., & Zhou, J. (2019). Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. Bioorganic & medicinal chemistry, 27(17), 3846–3852.
[3] Zhang, B., Wang, X., Wang, L., Chen, S., Shi, D., & Wang, H. (2016). Molecular Mechanism of the Flavonoid Natural Product Dryocrassin ABBA against Staphylococcus aureus Sortase A. Molecules (Basel, Switzerland), 21(11), 1428.
[4] Fu, R. H., Wang, Y. C., Liu, S. P., Shih, T. R., Lin, H. L., Chen, Y. M., Tsai, R. T., Tsai, C. H., Shyu, W. C., & Lin, S. Z. (2014). Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival. Cell transplantation, 23(4-5), 641–656.
[5] Jin, Z., Wang, W. F., Huang, J. P., Wang, H. M., Ju, H. X., & Chang, Y. (2016). Dryocrassin ABBA Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells Through a Caspase-Dependent Mitochondrial Pathway. Asian Pacific journal of cancer prevention : APJCP, 17(4), 1823–1828.
[6] Ou, C., Zhang, Q., Wu, G., Shi, N., & He, C. (2015). Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. Frontiers in microbiology, 6, 592.
[7] Li, B., Jin, Y., Xiang, H., Mu, D., Yang, P., Li, X., Zhong, L., Cao, J., Xu, D., Gong, Q., Wang, T., Wang, L., & Wang, D. (2019). An Inhibitory Effect of Dryocrassin ABBA on Staphylococcus aureus vWbp That Protects Mice From Pneumonia. Frontiers in microbiology, 10, 7.
| Cell experiment [1]: | |
Cell lines | mouse bone marrow-derived DCs (mBM-DCs) |
Preparation Method | mBM-DCs were pretreated with 10 or 20μM Dryocrassin ABBA for 1h. After 1h of incubation, the cells were washed twice using PBS, followed by stimulation with 100ng/mL LPS for 20h. Media and cells were collected for subsequent evaluation of DC activation and analysis of protein expression. Three replicates were included in each experiment. |
Reaction Conditions | 10 or 20μM；1h |
Applications | Dryocrassin ABBA significantly reduced the LPS-induced emission of tumor necrosis factor-a, interleukin-6, and interleukin-12p70. The expression of LPS-induced major histocompatibility complex class II, CD40, and CD86 on DCs was also blocked by Dryocrassin ABBA. |
| Animal experiment [2]: | |
Animal models | SPF BALB/C female mice |
Preparation Method | 120 female BALB/C mice were randomly divided into six groups with 20 mice per group. The control group was administrated saline intra-nasally, while the remaining five groups were inoculated intra-nasally with 104.5 ELD50 H5N1 viruses in 100μl saline. On day 2 post inoculation mice received 0.2ml of Dryocrassin ABBA or amantadine hydrochloride by oral gavages. The dosages of the three Dryocrassin ABBA groups were 12.5, 18, and 33mg/kg body weight, and 20mg/kg body weight of amantadine hydrochloride was used as the positive drug control. Mice were given drugs for 7 days from Day 2 to Day 8. Meanwhile, the untreated and control groups received equivalent amounts of physiological saline daily. Body weight, activity, mortality rate, and survival time were monitored daily for 14 days post inoculation. |
Dosage form | 12.5, 18, and 33mg/kg/day for 7 days; p.o. |
Applications | Dryocrassin ABBA significantly reduced mortality, prolonged survival rate, and increased body weight throughout the infection period. 33 and 18mg/kg Dryocrassin ABBA have decreased lung index and virus loads, and significantly increased MCP-1 and IL-10 while significantly decreased IL-12, IL-6, IFN-γ and TNF-α compared to the untreated group. |
References: | |
| Cas No. | 12777-70-7 | SDF | |
| Chemical Name | 2-acetyl-4-[[3-[[3-[(5-acetyl-2,6-dihydroxy-3,3-dimethyl-4-oxocyclohexa-1,5-dien-1-yl)methyl]-5-butanoyl-2,4,6-trihydroxyphenyl]methyl]-5-butanoyl-2,4,6-trihydroxyphenyl]methyl]-3,5-dihydroxy-6,6-dimethylcyclohexa-2,4-dien-1-one | ||
| Canonical SMILES | CCCC(=O)C1=C(C(=C(C(=C1O)CC2=C(C(C(=O)C(=C2O)C(=O)C)(C)C)O)O)CC3=C(C(=C(C(=C3O)C(=O)CCC)O)CC4=C(C(C(=O)C(=C4O)C(=O)C)(C)C)O)O)O | ||
| Formula | C43H48O16 | M.Wt | 820.29 |
| Solubility | Storage | -20°C, protect from light | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2191 mL | 6.0954 mL | 12.1908 mL |
| 5 mM | 243.8 μL | 1.2191 mL | 2.4382 mL |
| 10 mM | 121.9 μL | 609.5 μL | 1.2191 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)